Sigma Enacts Sustainable Strategy

Australian pharmaceutical and healthcare company Sigma Pharmaceuticals is concentrating on high-margin products to maintain financial health in an increasingly challenging operating environment. Despite a fall in profit last year, it is BMI's view that Sigma's overall strategy is sound, typified by its recent acquisition of compatriot player Orphan Holdings, which gave it an enhanced presence in the lucrative hospital market.

To read the full article, please choose one of the following options: